

IN THE CLAIMS:

1-20. (Cancelled).

21. (Currently Amended). A method of slowing mucopolysaccharide disease progression in a patient in need thereof comprising administering ~~a therapeutically effective amount of an~~ inhibitor of glucosylceramide synthase in an efficacious amount to slow mucopolysaccharide disease progression in a patient ~~synthesis~~, wherein the inhibitor of glucosylceramide synthase ~~synthesis~~ is an imino sugar.

22. (Previously Presented). The method according to claim 21 wherein the mucopolysaccharide disease is selected from the group consisting of MPS I (MPS IH, IS or IH/S), MPS II, MPS IIIA, IIIB, IIIC or IIID, MPS IVA or IVB, MPS VI and MPS VII.

23-24. (Canceled).

25. (Previously Presented). The method according to claim 21 wherein the inhibitor is N-butyldeoxynojirimycin or N-butyldeoxygalactonojirimycin.

26. (Previously Presented). The method according to claim 25 wherein the inhibitor is N-butyldeoxynojirimycin.

27. (Canceled).

28. (Currently Amended). A method of reducing neuronal glycolipid storage in mucopolysaccharide disease in a patient in need thereof comprising administering ~~a therapeutically effective amount of an~~ inhibitor of glucosylceramide synthase in an efficacious amount to reduce neuronal glycolipid storage in mucopolysaccharide disease in a patient ~~synthesis~~, wherein the inhibitor of glucosylceramide synthase ~~synthesis~~ is an imino sugar.

29. (Previously Presented). The method according to claim 28 wherein the mucopolysaccharide disease is selected from the group consisting of MPS I (MPS IH, IS or IH/S), MPS II, MPS IIIA, IIIB, IIIC or IIID, MPS IVA or IVB, MPS VI and MPS VII.

30-31. (Canceled).

32. (Previously Presented). The method according to claim 28 wherein the inhibitor is N-butyldeoxynojirimycin or N-butyldeoxygalactonojirimycin.

33. (Previously Presented). The method according to claim 32 wherein the inhibitor is N-

butyldeoxynojirimycin.

34. (Canceled).

35. (Canceled).

36. (Currently Amended). A method of reducing pathological features resulting from glycolipid accumulation in a patient with a mucopolysaccharide disease comprising administering ~~a therapeutically effective amount of~~ an inhibitor of glucosylceramide synthase in an efficacious amount to reduce pathological features resulting from glycolipid accumulation in a patient with a mucopolysaccharide disease ~~synthesis~~, wherein the inhibitor of glucosylceramide synthase ~~synthesis~~ is an imino sugar.

37. (Currently Amended). A method for improving survival of a patient with a mucopolysaccharide disease comprising administering ~~a therapeutically effective amount of~~ an inhibitor of glucosylceramide synthase in an efficacious amount to improve survival of a patient with mucopolysaccharide disease ~~synthesis~~, wherein the inhibitor of glucosylceramide synthase ~~synthesis~~ is an imino sugar.